Thu, Jan 29, 2015, 5:51 PM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Financial News From Zacks Small Cap Research

  • ANTB: AntriaBio Prepares For Clinical Study Of Once Weekly Insulin Zacks Small Cap Research - Wed, Jan 28, 2015 11:00 AM EST

    The company has been very busy over the past month securing financing and completing preclinical PK/PD studies in hope to advance its lead candidate, AB101, into human clinical trials later this year. AntriaBio is developing AB101, a product that aims to be the first once-weekly basal insulin. AB101 is a formulation of …

  • By Steven Ralston, CFA OTC:GRDH Guardian 8 Holdings (OTC:GRDH)  is the developer and manufacturer of the  G8 Pro V2 , a non-lethal security device designed for use in the professional security industry. ...

  • SANW: Company sells land and pays down some convertible debt. Zacks Small Cap Research - Mon, Jan 26, 2015 11:15 PM EST

    On Jan. 26, 2015 the company (SANW) announced the sale of two properties in California for an aggregate of $7.3 million, the pay down of a mortgage of $2.3 million and the redemption of $5 million of the recently issued convertible debenture. The two properties sold were 759 acres in Calipatria in the Imperial Valley and …

  • SDIG: New Initiatives Could Further Differentiate Offering and Help Drive Ad Revenue Zacks Small Cap Research - Fri, Jan 23, 2015 11:30 AM EST

    As an emerging Internet radio and digital media platform, StationDigital aspires to become the first device agnostic, multimedia global broadcast platform offering a broad range of entertainment choices in a free-to-consumer service. We are optimistic about initiatives StationDigital announced this week, including creating …

  • CBMX: Overhyped Risks Provide Attractive Entry Point Zacks Small Cap Research - Thu, Jan 22, 2015 9:35 AM EST

    The lawsuit was dismissed by the court later in 2011.  An appeals court reversed this decision in late 2012 and the case was remanded to the Superior Court of California.  Strathman filed an amended complaint and, following an unsuccessful motion by CBMX for the court to rule in their favor without a trial, on January 6, …

  • LMD.V: Revenue +240% in 2014, +90% in 2015? Zacks Small Cap Research - Thu, Jan 22, 2015 9:20 AM EST

    By Brian Marckx, CFA TSX:LMD.V OTC:LEDIF 2014 Revenue Preannouncement: $9.7M In Orders, In-Line w/ Expectations, Should Recognize $8.5M in 2014 This morning (1/21/2015) LED Medical (TSX:LMD.V) (OTC:LEDIF) ...

  • PBIO: With Boosted Balance Sheet, PBIO Ready to Accelerate Sales Zacks Small Cap Research - Wed, Jan 21, 2015 1:30 PM EST

    We noticed that all of the Company's officers and board members participated in the transaction. - One warrant to purchase 500 shares of common stock at an exercise price of $0.3125 per share, with a term expiring on November 12, 2017.

  • NVIV: InVivo Patient No.1 Shows ‘Unexpected’ Gains Zacks Small Cap Research - Wed, Jan 21, 2015 1:00 PM EST

    On January 21, 2015, InVivo Therapeutics (NVIV) provided an update on the status of the first patient enrolled in the company’s ongoing pilot study of its investigational Neuro-Spinal Scaffold (NSS) for the treatment of acute spinal cord injury. This is primarily a safety study (NCT02138110), with the main goal to evaluate …

  • Lion Biotech: An Emerging Biotech Company Focused On TIL Therapy for Cancers Zacks Small Cap Research - Tue, Jan 20, 2015 2:15 PM EST

    In December 2014, Lion Biotechnologies (LBIO) named Elma Hawkins, PhD to serve as its new president and chief executive officer, effective January 1, 2015. Dr. Hawkins is a veteran in the biopharmaceutical industry. Dr. Hawkins has served as Lion’s president and chief operating officer since August 2014.  From February …

  • FMD: Cost Savings to Drive Substantial Improvement in 2016 Results Zacks Small Cap Research - Tue, Jan 20, 2015 12:00 PM EST

    The First Marblehead Corporation (FMD) reported its fiscal 2015 first quarter results for the period ended September 30, 2014, posting a net loss from continuing operations of $10.5 million, or a loss per share of $0.92. The company had its initial public offering on the NYSE in October 2003.

  • EDT.TO: Initiating Coverage of Spectral Medical: Toraymyxin Column For Severe Sepsis Zacks Small Cap Research - Tue, Jan 20, 2015 11:30 AM EST

    Spectral is developing the Toraymyxin column for the treatment of severe sepsis. The Toraymyxin column is a polymyxin B loaded absorption column designed to reduce blood endotoxin levels in sepsis patients. Sepsis is a potentially life-threatening condition caused by an overwhelming immune response to an infection. While …

  • APHB: AmpliPhi Provides Shareholder Update Zacks Small Cap Research - Fri, Jan 16, 2015 3:00 PM EST

    On Monday, January 5, 2015, AmpliPhi Biosciences (APHB) held a conference call to update shareholders on the company’s accomplishments during 2014, as well as the goals for the upcoming year. AmpliPhi is focused on the discovery, development and commercialization of bacteriophage treatments for bacterial infections. In …

  • BMRA: Asia Still Soft But Wrinkles Now Ironed Out Zacks Small Cap Research - Fri, Jan 16, 2015 12:00 PM EST

    By Brian Marckx, CFA OTC:BMRA Q2 Results : Asia Remains Weak But Not For Long. GI Test Could Be a Long-Term Winner… Biomerica (OTC:BMRA) filed their 10-Q for the fiscal 2015 second quarter ending November ...

  • MDGN: Positive MDGN-201 Data Through 7 Months Zacks Small Cap Research - Fri, Jan 16, 2015 9:30 AM EST

    In mid-October Medgenics (MDGN) presented initial results from the MDGN-201 study which is using TARGTEPO with a new generation vector to produce natural erythropoietin in patients with chronic kidney disease and end-stage renal disease.  TARGTEPO produces natural erythropoietin.  If effective TARGTEPO could potentially …

  • CDTi (CDTI) has announced the launch of a new website to provide information about the benefits of the company's replacement filters together with links to video, sales literature and a product catalog. Industry sources report that the market for after-treatment maintenance and repair was $500 million in 2010 and is expected …

  • SANW: Senior management from Pioneer integrated into S&W Seed. Zacks Small Cap Research - Fri, Jan 16, 2015 9:00 AM EST

    S&W Seed (SANW) has announced the appointment of Dr. Mark Smith to the position of Director of Breeding and Genetics. Dr. Smith will have primary responsibility for  continued R&D on the dormant alfalfa varieties acquired from Pioneer Du Pont and will be working with S&W Seed's integrated R&D group on further research …

  • GPDB: New Initiatives to Tap Growing Organic Market Zacks Small Cap Research - Fri, Jan 16, 2015 7:30 AM EST

    Several recent initiatives by Green PolkaDot Box (GPDB), a membership club that offers organic and natural products to its members at attractive prices, have shown early momentum, we believe. These include the company’s recently introduced Health Merchant program, marketing for appetite suppressant Appethyl and the positive …

  • PRGB: New Analytics Platform Further Expands PRGB's Capabilities Zacks Small Cap Research - Wed, Jan 14, 2015 12:00 PM EST

    By Brian Marckx, CFA OBB:PRGB Protea Launches New Analytics Platform During a presentation at Biotech Showcase, a premier annual life sciences conference held in San Francisco each January, Protea Biosciences ...

  • NHC.TO: Nobilis Health issues Guidance for 2015; Zacks raises target Zacks Small Cap Research - Wed, Jan 14, 2015 9:45 AM EST

    By Steven Ralston, CFA TSX:NHC.TO Nobilis Health Corp. (TSX:NHC.TO), formerly Northstar Healthcare Inc., pre-announced estimated sales for the fourth quarter ending December 31, 2014. Fourth quarter’s ...

  • SNGX: With Orphan and Fast Track Designation, SGX301 is Ready to Move to Phase III Zacks Small Cap Research - Wed, Jan 14, 2015 9:20 AM EST

    By Grant Zeng, CFA OBB:SNGX The Designation of Fast Track and Orphan Drug Recently, Soligenix (OBB:SNGX) received from the FDA " Fast Track " designation for its SGX301 development program for ...

  • AMBS: Amarantus Acquires Rights To MS Diagnositic Zacks Small Cap Research - Tue, Jan 13, 2015 2:15 PM EST

    By Jason Napodano, CFA & David Bautz, PhD OTC:AMBS On Monday, January 12, 2015, Amarantus Bioscience Holdings, Inc. (OTC:AMBS)  announced  the acquisition of DioGenix, Inc., a company with a pipeline of ...

  • CEMI: Significant Pipeline Progress Zacks Small Cap Research - Tue, Jan 13, 2015 12:30 PM EST

    By Brian Marckx, CFA NASDAQ:CEMI Significant Pipeline Progress Chembio (NASDAQ:CEMI) has made substantial progress over the last few months with development of its pipeline.  This includes development ...

  • BLFS: New Product Sales Record, 2015 Looks Promising Zacks Small Cap Research - Tue, Jan 13, 2015 10:00 AM EST

    By Brian Marckx, CFA NASDAQ:BLFS Q4 2014 Revenue Pre-Announcement: Record Product Sales, Initial Contribution from Somahlution   This morning (1/12/15) BioLife Solutions (NASDAQ:BLFS) pre-announced revenue ...

  • By Anthony Schwartz, PhD OBB:ENUM Enumeral Biomedical Holdings, Inc. (OBB:ENUM)  is a biotechnology company focused on discovering and developing novel immunotherapies for the treatment of cancer and autoimmune ...

  • ILIU Building Out Companion Diagnostics Portfolio Zacks Small Cap Research - Fri, Jan 9, 2015 10:45 AM EST

    By Brian Marckx, CFA OTC:ILIU Interleukin Genetics’(OTC:ILIU) Heart Health Genetic Test was used in a clinical trial to assess whether interleukin-1 (IL-1) genotype status can help predict risk of coronary ...

  • SANW: Pioneer Du Pont pays $22 million to S&W Seed. Zacks Small Cap Research - Fri, Jan 9, 2015 10:10 AM EST

    By Ian Gilson, PhD, CFA NADSAQ:SANW Today S&W Seed (NASDAQ:SANW) held a conference call to discuss the purchase of Pioneer DuPont's alfalfa operations. S&W Seed will receive a prepayment for the delivery ...

  • By Jason Napodano, CFA NASDAQ:NBIX   On January 8, 2015, AbbVie Inc. (ABBV) and Neurocrine Biosciences (NASDAQ:NBIX) reported  positive top-line data  from a Phase 3 trial evaluating the safety and efficacy ...

  • VNRX Stock Moving Up On Clinical Data Zacks Small Cap Research - Wed, Jan 7, 2015 12:00 PM EST

    By Brian Marckx, CFA OTC:VNRX VolitionRx (OTC:VNRX) continues to expand the potential utility of their NuQ technology to include more types of cancer.  Validation of the technology was initially largely ...

  • Advaxis (ADXS), a clinical stage biopharmaceutical company, announced on January 7, 2015 that it has entered into an agreement with the GOG Foundation for the use of ADXS-HPV in cervical cancer. The GOG foundation is a non-profit entity that supports clinical research for the treatment of ovarian and other gynecologic …

  • MMMB: Zacks initiates coverage of MamaMancini’s with Buy rating Zacks Small Cap Research - Wed, Jan 7, 2015 9:30 AM EST

    MamaMancini’s Holdings is a growth company in the specialty food industry. Management is aggressively pursuing strategies to build the MamaMancini’s brand and drive sales growth through 1) the addition of new retail locations, 2) increasing the number of shelf placements at each location and 3) new product introductio …

  • CRBP: Corbus Pharma Tackles Fibrosis With Novel Molecule Zacks Small Cap Research - Tue, Jan 6, 2015 10:40 AM EST

    We are initiating coverage of Corbus Pharmaceuticals, Inc. (CRBP) with an Outperform rating and a price target of $6.00. Corbus is developing Resunab™ (ajulemic acid) for the treatment of rare life-threatening chronic inflammatory conditions. The company is initially focusing on cystic fibrosis and diffuse systemic sclerosis …

  • BCLI: Brainstorm Takes Major Leap Forward In Battle vs. ALS Zacks Small Cap Research - Tue, Jan 6, 2015 9:15 AM EST

    Below we give a brief overview of ALS, the Phase 2a clinical trial final data, and what the results may portend for the future of NurOwn™. ALS is a rapidly progressing neurodegenerative disease whereby the nerve cells in the brain and spinal cord that control muscle movement degenerate. This rapid degeneration of the …

  • Advaxis (ADXS), a clinical stage biopharmaceutical company, announced on January 5, 2015 the submission of an Investigational new drug (IND) application to the FDA to initiate a clinical trial for HER2 expressing solid tumors using its novel immunotherapy, ADXS-HER2. Advaxis expects to receive a response from the FDA within …

  • To pay for the Du Pont Pioneer acquisition S&W (SANW) has raised $31.7 million through a combination of convertible debt with warrants and the sale of stock. The increase in shares, assuming the convertible is converted to common stock, is in line with our assumptions and our estimates have not been changed. The company …

  • On December 24th 2014, the Conkwest Corporation announced that Dr. Patrick Soon-Shiong entered into an agreement to purchase $48 million in Conkwest’s Class A common stock. Dr. Soon-Shiong is a physician scientist and entrepreneur whom founded NantWorks, an umbrella entity whose mission is to develop an integrated, fact-based, …

  • ATOS: A Pure Play Breast Care Company with Great Potential to Grow Zacks Small Cap Research - Wed, Dec 24, 2014 9:15 AM EST

    Atossa’s (ATOS) subsidiary, the National Reference Laboratory for Breast Health, Inc. (the NRLBH), is offering pharmacogenetics (PG) testing for patients. Current capacity at NRLBH can process approximately 5,000 pharmacogenetics tests per month and can increase capacity by hiring additional employees and adding additional …

  • AMBS: Amarantus Receives Orphan Drug Designation for MANF in Retinitis Pigmentosa Zacks Small Cap Research - Tue, Dec 23, 2014 4:00 PM EST

    According to the U.S. FDA's Website, Amarantus BioScience Holdings, Inc (AMBS) preclinical drug candidate, human recombinant mesencephalic astrocyte derived neurotrophic factor (MANF), was granted an Orphan Drug designation for the treatment of Retinitis Pigmentosa (RP) on December 22, 2014. Amarantus confirmed the news …

  • CPKF: Third Quarter Results Better Than Anticipated Zacks Small Cap Research - Tue, Dec 23, 2014 12:00 PM EST

    All per share data in this report have been adjusted for a 5-for-6 stock split, paid to shareholders in mid-October 2014. This was better than our estimate, which had called for a $0.1 million increase in net earnings to $1.6 million (off by $0.1 million) and a $0.02 rise in diluted EPS to $0.40 (off by $0.02).

  • S&W Seed (SANW) announced on December 19, 2014 that it will acquire the alfalfa operations of Du Pont Pioneer. S&W Seed will purchase all of Pioneer's non-GMO alfalfa operations, assets and research facilities.

  • JAMN: Jammin Java reports FY3Q & management outlines growth strategy for next FY Zacks Small Cap Research - Mon, Dec 22, 2014 9:00 AM EST

    Jammin Java (JAMN) d/b/a Marley Coffee reported financial results for the third fiscal quarter ending October 30, 2014. The impetus of the awards is bolstering the efforts of Blue Mountain Coffee (Europe) Limited (Marley’s UK partner), in their plans to further expand into OCS and the Food Service industry through the …

  • EPRS: Epirus Biopharma: An Intriguing Global Biosimilar Play Zacks Small Cap Research - Fri, Dec 19, 2014 9:00 AM EST

    Epirus Biopharmaceuticals (EPRS) is a biopharma company focused on developing, manufacturing, and commercializing biosimilar therapeutics in various jurisdictions worldwide. The company's strategy is centered on launching biosimilar products in the developed markets (U.S., Europe), accessing growth in local production …

  • Enumeral Biomedical Holdings, Inc. (ENUM) is a biotechnology company focused on discovering and developing novel immunotherapies for the treatment of cancer and autoimmune diseases. On December 18, 2014, Enumeral announced it entered into a partnership with Merck to identify functional responses of Merck’s immuno-therapeutics …

  • CTSOD: Fresenius Adds More Than Just Marketing Muscle Zacks Small Cap Research - Thu, Dec 18, 2014 10:00 AM EST

    Fresenius’ distribution reach including in France, which is the second largest market for medical devices in Europe, will almost certainly be a material needle-mover of CTSO’s revenue.  But Fresenius brings much more than just a large dialysis service/equipment/supplies network.  Fresenius is THE leader in dialysis, has …

  • ASPX: Auspex Pharma Hits A Homerun In Phase 3 Huntington's Chorea Trial Zacks Small Cap Research - Wed, Dec 17, 2014 12:00 PM EST

    The two Phase 3 trials, First-HD and Arc-HD, studied SD-809, a deuterium-containing analog of tetrabenazine, head-to-head vs. placebo for the treatment of chorea with HD and in transitioning patients on stable doses of tetrabenazine to SD-809, respectively. We initiated coverage of Auspex Pharma in November 2014 with a …

  • APDN Reports Record Revenue for Fiscal Year 2014 Zacks Small Cap Research - Wed, Dec 17, 2014 9:15 AM EST

    By Grant Zeng, CFA NASDAQ:APDN On December 16, 2014, Applied DNA Sciences (NASDAQ:APDN) reported its year-end results of fiscal 2014 ended September 30, 2014. For the fiscal year ended September 30, 2014, ...

  • NVIV: FDA Allows InVivo Therapeutics To Expedite Enrollment For Spinal Injury Device Zacks Small Cap Research - Tue, Dec 16, 2014 3:00 PM EST

    On December 16, 2014, InVivo Therapeutics (NVIV) released some very positive news with respect to the company's going pilot study (NCT02138110) testing InVivo's Neural-Spina Scaffolding ("NSS") for the treatment of complete traumatic spinal cord injury. It's primarily a safety study, with investigators and the FDA looks …

  • VPIG: Believe Larger Partner Could Help Grow Oink Zacks Small Cap Research - Tue, Dec 16, 2014 1:00 PM EST

    Last week, Virtual Piggy (VPIG) announced that its board had authorized management to evaluate strategic alternatives. We believe Virtual Piggy could be an interesting acquisition candidate for a larger technology company or payment provider seeking to expand within the YA market in a regulatory compliant way. Many online …

  • SRNE: Sorrento Establishes Collaboration with Nantworks Zacks Small Cap Research - Tue, Dec 16, 2014 9:25 AM EST

    On Dec. 15, 2014, Sorrento (SRNE) announced that it has entered into a binding agreement with NantWorks founder, physician scientist, and biotechnology entrepreneur Dr. Patrick Soon-Shiong. Pursuant to the agreement, NantWorks and Sorrento will establish a first joint venture to jointly develop next generation immunotherapies …

  • Advaxis (ADXS), a clinical stage biopharmaceutical company, announced on December 15, 2014 that the FDA has cleared its Investigational New Drug (IND) application for combinational use of ADXS-HPV and MedImmune’s anti-PD-L1 immune checkpoint inhibitor, MEID4736. The Phase I/II trial will begin enrollment in early 2015 …

  • PURE Reports Fiscal First Quarter 2015 Financial Results Zacks Small Cap Research - Fri, Dec 12, 2014 12:45 PM EST

    By Grant Zeng, CFA OTC:PURE On Dec 11, 2014, PURE (OTC:PURE) reported financial results for the fiscal 1Q15 ended October 31, 2014. Revenues for the fiscal 1Q15 were $117,000, compared to $115,000 for ...

Next >>